HK55896A - Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus - Google Patents

Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus Download PDF

Info

Publication number
HK55896A
HK55896A HK55896A HK55896A HK55896A HK 55896 A HK55896 A HK 55896A HK 55896 A HK55896 A HK 55896A HK 55896 A HK55896 A HK 55896A HK 55896 A HK55896 A HK 55896A
Authority
HK
Hong Kong
Prior art keywords
retrovirus
ene
deoxythymidin
composition according
didehydrothymidine
Prior art date
Application number
HK55896A
Other languages
German (de)
English (en)
Inventor
Lin Tai-Shun
William H. Prusoff
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25478432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK55896(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University filed Critical Yale University
Publication of HK55896A publication Critical patent/HK55896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

  1. Composition pharmaceutique pour le traitement d'animaux à sang chaud infectés par un rétrovirus, comprenant, comme ingrédient actif, une quantité anti-rétrovirale efficace de désoxy-3' thymidinène-2', soit seul, soit en mélange avec des additifs usuels, tels que des diluants solides, liquides ou sous forme de gaz liquéfiés.
  2. Composition selon la revendication 1, dans laquelle le rétrovirus est le virus de la leucémie murine de Moloney.
  3. Composition selon la revendication 1, dans laquelle le rétrovirus est HTLV III/LAV.
  4. Composition selon l'une quelconque des revendications 1 à 3, contenant 0,5 à 90% dudit ingrédient actif.
  5. Composition selon l'une quelconque des revendications 1 à 4, sous la forme d'une solution aqueuse physiologiquement isotonique, stérile.
  6. Composition selon la revendication 5, contenant 0,5 à 90% dudit ingrédient actif.
  7. Composition selon l'une quelconque des revendications 1 à 6, sous la forme d'un médicament se présentant sous la forme d'unités de dosage, telles que sous la forme de pastilles, pilules, dragées, capsules, gélules, ampoules ou suppositoires.
  8. Utilisation du désoxy-3' thymidinène-2' ou d'une composition pharmaceutique telle que définie à l'une quelconque des revendications 1 à 7, pour la préparation d'un médicament pour le traitement d'animaux à sang chaud infectés par un rétrovirus.
HK55896A 1986-12-17 1996-03-28 Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus HK55896A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/942,666 US4978655A (en) 1986-12-17 1986-12-17 Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses

Publications (1)

Publication Number Publication Date
HK55896A true HK55896A (en) 1996-04-03

Family

ID=25478432

Family Applications (1)

Application Number Title Priority Date Filing Date
HK55896A HK55896A (en) 1986-12-17 1996-03-28 Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus

Country Status (22)

Country Link
US (1) US4978655A (fr)
EP (1) EP0273277B1 (fr)
JP (1) JPH07116041B2 (fr)
KR (1) KR960000433B1 (fr)
AT (1) ATE77554T1 (fr)
AU (1) AU593405B2 (fr)
CA (1) CA1293447C (fr)
DE (1) DE3780016T2 (fr)
DK (1) DK174627B1 (fr)
EG (1) EG19157A (fr)
ES (1) ES2038650T3 (fr)
FI (1) FI875544A7 (fr)
GR (1) GR3005691T3 (fr)
HK (1) HK55896A (fr)
IE (1) IE60866B1 (fr)
IL (1) IL84790A (fr)
LU (1) LU88822I2 (fr)
NL (1) NL960024I2 (fr)
NZ (1) NZ222935A (fr)
PH (1) PH26380A (fr)
PT (1) PT86346B (fr)
ZA (1) ZA877171B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US6207650B1 (en) 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
CA2189097A1 (fr) 1995-11-15 1997-05-16 Pin-Fang Lin Composition et methode pour le traitement de l'infection retrovirale
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
WO2000016625A1 (fr) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Compositions medicamenteuses antivirales contenant des sels inorganiques de lithium
EE200200564A (et) * 2000-03-30 2004-06-15 Bristol-Myers Squibb Company Stavudiini sisaldavad toimeainet aeglustatult vabastavad graanulid
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
CA2514466C (fr) * 2003-02-19 2015-05-26 Yale University Analogues de nucleosides antiviraux et methodes de traitement d'infections virales, notamment d'infections a vih
US20040200730A1 (en) * 2003-04-14 2004-10-14 Kyo Jibiki Hydrometallurgical copper recovery process
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
WO2007026156A1 (fr) * 2005-08-31 2007-03-08 Cipla Limited Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la névirapine
DK2364314T3 (da) 2008-12-09 2014-05-12 Gilead Sciences Inc Modulatorer af toll-lignende receptorer
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
WO2017048727A1 (fr) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3322747A (en) * 1965-04-01 1967-05-30 Merck & Co Inc Thionocarbonate nucleosides
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS5943550B2 (ja) * 1975-08-29 1984-10-23 田辺製薬株式会社 不飽和ヌクレオシドの製法
DE3515870A1 (de) * 1985-05-03 1986-11-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 5-fluortoluol-2,4-disulfochlorid
US4710492A (en) * 1986-06-23 1987-12-01 Yale University 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
NL8700089A (nl) * 1987-01-15 1988-08-01 Stichting Rega V Z W Therapeutische toepassing van dideoxythymidine en dideoxythymidineen.
DE3806633A1 (de) * 1987-09-01 1989-03-09 Bayer Ag Antivirales mittel
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
JPH0227782A (ja) * 1988-07-15 1990-01-30 Hikari Gijutsu Kenkyu Kaihatsu Kk 半導体発光素子
JPH0438727A (ja) * 1990-06-04 1992-02-07 Sharp Corp 光学式ピックアップ装置の対物レンズ塵埃付着防止機構

Also Published As

Publication number Publication date
NL960024I2 (nl) 1997-06-02
DK557087A (da) 1988-06-18
DK174627B1 (da) 2003-07-28
ATE77554T1 (de) 1992-07-15
NL960024I1 (nl) 1996-12-02
DE3780016T2 (de) 1992-12-24
IL84790A (en) 1993-03-15
FI875544L (fi) 1988-06-18
NZ222935A (en) 1990-09-26
JPS63215632A (ja) 1988-09-08
US4978655A (en) 1990-12-18
JPH07116041B2 (ja) 1995-12-13
IL84790A0 (en) 1988-05-31
AU593405B2 (en) 1990-02-08
LU88822I2 (fr) 1997-01-06
AU8090087A (en) 1988-06-23
GR3005691T3 (fr) 1993-06-07
KR960000433B1 (ko) 1996-01-06
DK557087D0 (da) 1987-10-23
PT86346A (en) 1988-01-01
FI875544A0 (fi) 1987-12-16
FI875544A7 (fi) 1988-06-18
CA1293447C (fr) 1991-12-24
IE873245L (en) 1988-06-17
EP0273277A3 (en) 1989-09-13
EP0273277B1 (fr) 1992-06-24
DE3780016D1 (de) 1992-07-30
PH26380A (en) 1992-06-01
ES2038650T3 (es) 1993-08-01
EG19157A (en) 1994-09-29
EP0273277A2 (fr) 1988-07-06
PT86346B (pt) 1990-11-07
ZA877171B (en) 1988-03-24
KR880007079A (ko) 1988-08-26
IE60866B1 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
EP0273277B1 (fr) Composition pharmaceutique contenant la 3'-déoxythimidin-2'-ène(3'-dioxy-2',3'-didéhydrothymidine) pour le traitement des patients infectés par des rétrovirus
US4916122A (en) 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
CA1336088C (fr) 1- (3'-substituant-2', 3'-didesoxy-d-ribofuranosyl) thymine et uracile
AU598575B2 (en) Retrovirus treatments
US4681933A (en) 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4892865A (en) Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US4841039A (en) 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4710492A (en) 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
EP0261595B1 (fr) Composition pharmaceutique contenant du 2',3'-didéoxy-cytidin-2'-éne(2',3'-didéoxy-2',3'-didéhydrocytidine) pour le traitement de patients infectés au rétrovirus
US5446029A (en) Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
US5190926A (en) 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
US4999360A (en) Method of inhibiting virus
PH26909A (en) Pyrimidine derivatives
US5089520A (en) Method of inhibiting virus
US6001818A (en) Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehydrocytidine) in treating patients infected with retroviruses
US5026688A (en) Novel AZT analogs
US5051498A (en) Lipophilic 2', 3'-dideoxynucleoside prodrug derivatives for the inhibition of replication of the AIDS virus and other retroviruses
US5043416A (en) Method of inhibiting virus
CA1327005C (fr) Nucleosides therapeutiques
EP0309560A1 (fr) Nucleosides et analogues de nucleosides, compositions et procedes pharmaceutiques permettant la preparation des composes.
IE67037B1 (en) Novel medicinal compounds

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20071210